Crisaborole 2% topical ointment for vitiligo

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 15 May 2026: Trial started, NCT07904910
  2. 29 Oct 2026: Trial registered, NCT07904910

The trials

NCT07904910: Evaluation of Crisaborole 2% Versus Tacrolimus 0.1% Each Combined With Excimer Light in the Treatment of Stable Non-segmental Facial Vitiligo: a Prospective Randomized Controlled Study.

State
Under way
Phase
Phase 3
People
35 planned
Started
15 May 2026
Primary completion
15 Nov 2026
Arms
Crisaborole 2% ointment combined with Excimer light therapy
Results
None posted
  1. 15 May 2026: Trial started
  2. 29 Oct 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.